June 12, 2025

Vegetarian Diet Linked to Lower Cancer Incidence

A large North American cohort study found that vegetarian diets were associated with lower risks of several site-specific cancers, including colorectal, stomach, breast, prostate, and lymphoproliferative cancers.

Conexiant

June 12, 2025

What's the Best Scoring Method in CRC Prognosis?

Study of three systems finds that a simple tumor growth pattern scoring method independently predicts colon cancer–specific survival.

The Pathologist

June 06, 2025

Lower-Dose Treatment Effective in Anal Cancer Trial, Study

In a recent clinical trial, researchers found that a reduced-dose chemoradiotherapy regimen for early-stage anal cancer may be comparable to standard treatment in achieving short-term tumor response, while causing fewer serious side effects.

Conexiant

June 06, 2025

NRT’s Double-Edged Sword in Rectal Cancer

A large cohort study found neoadjuvant radiotherapy improved survival for rectal cancer patients but significantly increased the risk of permanent diverting stomas—especially in upper rectal tumors.

Conexiant

June 04, 2025

Chemo Killed Her. A Test Might've Saved Her.

A fatal enzyme deficiency turned a common chemo drug toxic. With testing available—but rarely used—are clinicians missing a lifesaving step?

KFF Health News

June 02, 2025

Exercise After Chemotherapy Improves Colorectal Cancer Survival

A long-term clinical trial found that structured exercise after colon cancer treatment improved survival outcomes and reduced recurrence rates, offering evidence to support physical activity as part of survivorship care.

Conexiant

June 02, 2025

ASCO 2025: Adding Atezolizumab to Adjuvant Chemotherapy Improves Disease-Free Survival in dMMR Colon Cancer

Results from the phase III ATOMIC study demonstrated that patients with deficient mismatch repair (dMMR) colon cancer who receive atezolizumab in addition to adjuvant chemotherapy experience a 50% red...

The ASCO Post

June 01, 2025

Diet Influences Survival After Stage III Colon Cancer, Dana-Farber Study Finds

A Dana-Farber study shows that an anti-inflammatory diet could extend overall survival after treatment for stage III colon cancer.

Dana-Farber

June 01, 2025

Adding Immune Checkpoint Inhibitor to Standard Chemotherapy Regimen Improves Outcomes in Stage 3 Colon Cancer, Study Finds

Combining standard adjuvant chemotherapy with an immune checkpoint inhibitor (atezolizumab) leads to a significant improvement in disease-free survival in a subset of patients with stage 3 colon cancer that is deficient in DNA mismatch repair (dMMR), Dana-Farber Cancer Institute investigator Dr. Jeffrey Meyerhardt and his colleagues report at the 2025 American Society of Clinical Oncology (ASCO) meeting.

Dana-Farber